Welzel, T.; Zapf, B.; Klotsche, J.; Satirer, Ö.; Benseler, S.M.; Kuemmerle-Deschner, J.B.
Optimized Treatment of Interleukin (IL-1)-Mediated Autoinflammatory Diseases: Impact of Disease Activity-Based Treatment Adjustments. J. Clin. Med. 2024, 13, 2319.
https://doi.org/10.3390/jcm13082319
AMA Style
Welzel T, Zapf B, Klotsche J, Satirer Ö, Benseler SM, Kuemmerle-Deschner JB.
Optimized Treatment of Interleukin (IL-1)-Mediated Autoinflammatory Diseases: Impact of Disease Activity-Based Treatment Adjustments. Journal of Clinical Medicine. 2024; 13(8):2319.
https://doi.org/10.3390/jcm13082319
Chicago/Turabian Style
Welzel, Tatjana, Beate Zapf, Jens Klotsche, Özlem Satirer, Susanne M. Benseler, and Jasmin B. Kuemmerle-Deschner.
2024. "Optimized Treatment of Interleukin (IL-1)-Mediated Autoinflammatory Diseases: Impact of Disease Activity-Based Treatment Adjustments" Journal of Clinical Medicine 13, no. 8: 2319.
https://doi.org/10.3390/jcm13082319
APA Style
Welzel, T., Zapf, B., Klotsche, J., Satirer, Ö., Benseler, S. M., & Kuemmerle-Deschner, J. B.
(2024). Optimized Treatment of Interleukin (IL-1)-Mediated Autoinflammatory Diseases: Impact of Disease Activity-Based Treatment Adjustments. Journal of Clinical Medicine, 13(8), 2319.
https://doi.org/10.3390/jcm13082319